Photo - Reglagene
57487

Reglagene

USA, Arizona
Market: Medicine, Another
Stage of the project: Prototype or product is ready

Date of last change: 25.05.2022
Show contacts
1
equalizer from 2000
help
Calculated and estimated occupancy of the project (more about ratings)
My rating
1
2
3
4
5
6
7
8
9
10
Average rating:
 

Idea

Reglagene is an oncology company that discovers and develops medicines for deadly brain cancers including glioblastoma and metastatic breast and lung cancers.

Current Status

With backing from The Arizona Commerce Authority, the Flinn Foundation, and the NIH, Reglagene became a fully operational biotech company in Tucson Arizona. The Reglagene team has successfully designed, manufactured, and tested over 600 cancer medicines, and are now choosing the best one to move forward into the clinic. After raising a seed round and convertible note, we recently signed a Series A term sheet with the Cancer Fund, a Phoenix based venture capital firm.

Problem or Opportunity

Currently there are 217 FDA approved cancer medicines available for patients. Out of these 217 cancer medicines, only 4 are indicated for life threatening brain cancer. Unfortunately, none of these have a significant survival benefit. Temozolomide, the standard of care chemotherapy and most widely used brain cancer medicine, only extends life by about 2.5 months. Temozolomide’s side effect profile is so harsh it causes patients to choose between palliative care and brief extended survival with major loss of quality of life.

Solution (product or service)

Reglagene is developing a therapeutically effective, orally administered, brain penetrant cancer medicine. We aim to reach patients as quickly as possible and utilize the FDA accelerated drug development and approval programs to reduce timelines and cost.

Patients will no longer choose between palliative care and toxic medicines that barely extend their lives. For the first time, an orally available, safer, broadly effective cancer agent will pass into the brain to defeat cancer.

Business model

Reglagene is a pre-revenue company. Our first opportunity to generate revenue will come through a co-development deal with a larger pharmaceutical company on our first asset. Co-development deals enable two companies to work together to develop a new therapy and are often struck during completion of the FDA-mandated studies to enable the first-in-human clinical trial. Reglagene is about six months from crossing the threshold in which a co-development deal is a viable possibility.

Incubation/Acceleration programs accomplishment

Arizona Innovation Challenge Venture Ready
Flinn Foundation Bioentrepreneurship Program
Mentored by the University of Arizona Center for Innovation
5,00
1
2
3
4
5
1 voice
Sign in/Sign up
arrow_back
EN
more_horiz
close
visibility120
star0
Add to favorites
Delete from favorites
share
close
thumb_up1
Like
Unlike
Idea
Current Status
Market
Problem or Opportunity
Solution (product or service)
Competitors
Advantages or differentiators
Finance
Invested in previous rounds, $
Business model
Money will be spent on
Offer for investor
Team or Management
Mentors & Advisors
Lead investor
Risks
Incubation/Acceleration programs accomplishment
Won the competition and other awards
Invention/Patent
Photos
Product Video